The Revi device intends to mitigate the potential adverse events associated with other surgical UUI therapies. Credit: ARMMY PICCA/shutterstock.com.

BlueWind Medical has announced the availability of its Revi implantable Tibial NeuroModulation (iTNM) device for urge urinary incontinence (UUI) in Springfield, Ohio, US.

The patient-centric, minimally invasive solution is now offered at Ohio Valley Surgical Hospital.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It is controlled by a battery-operated external wearable unit and can be implanted near the ankle in a single outpatient procedure, performed under local anaesthesia.

The Revi iTNM implant aims to minimise potential adverse events associated with other surgical UUI therapies.

Once implanted, the Revi device works by stimulating the posterior tibial nerve to alleviate symptoms of UUI.

See Also:

Patients can activate the implant using a lightweight wireless wearable that is placed around the ankle at their convenience, either once or twice daily, to provide the necessary stimulation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ohio Valley Surgical Hospital urologist Dr Eric Espinosa said: “I am thrilled to have a new solution to offer patients with Urge Incontinence—a common condition that has a profound impact on quality of life. Revi is proven to be a safe and effective therapy, reducing the number of leaks patients have and it stands out for its patient-centric design, allowing for tailored adjustments to optimise therapy.

“My patients like the fact that Revi is placed in the ankle region in an outpatient procedure under local anaesthesia, which makes it a more appealing and convenient option for them.”

In August 2023, the US Food and Drug Administration (FDA) granted a De Novo marketing request for the device to treat patients with symptoms of urgency incontinence alone or in combination with urinary urgency.

In October 2023, the American Medical Association CPT Editorial Panel announced the final Current Procedural Terminology code, 0817T, to describe the subfascial tibial neuromodulation implant procedure.

BlueWind Medical CEO Dan Lemaitre said: “Revi has the potential to revolutionise the treatment landscape for UUI by giving patients more control, comfort, and convenience.”